Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Ronja Hugg und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Teicoplanin, Prosthesis-Related Infections, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Dalbavancin, a lipoglycopeptide with a half-life of 150–200 h, is a promising treatment option for prosthetic joint infections (PJIs) and other orthopaedic implant-associated infections (IAIs) caused by multidrug-resistant staphylococci. However, in vitro studies have shown that when exposed to low concentrations of dalbavancin, staphylococcal strains resistant to dalbavancin can emerge, potentially affecting its effectiveness in cases of recurrent infection. To investigate whether dalbavancin-resistant staphylococci emerge in vivo following long-term dalbavancin treatment for PJIs or orthopaedic IAIs. Patients and methods Nineteen patients who had received long-term dalbavancin treatment (≥12 weeks) following PJI or orthopaedic IAI and 25 control patients scheduled for elective prosthetic joint surgery were sampled from the nares and perineum. Each sample was subcultured on Mueller–Hinton II agar plates containing various concentrations of dalbavancin (0.0, 0.125, 0.5, and 2.0 mg/L). The growth of staphylococcal colonies was analysed using MALDI-TOF, and the MIC values of dalbavancin were determined using the gradient test method.
Results
Among dalbavancin-treated patients, 4 out of 19 displayed staphylococcal species resistant to dalbavancin (MIC value >0.25 mg/L according to EUCAST breakpoint tables). These four were all Staphylococcus epidermidis isolates, three from the nares and one from the perineum, and displayed MIC values of 0.38, 0.38, 0.5, and 0.75 mg/L. No resistant staphylococci were detected in the samples from the control group (P = 0.029, Fisher's exact test).
Conclusions
The present study demonstrated the emergence of dalbavancin-resistant staphylococci following long-term treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Orthopedics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Sequencing and Bioinformatics, Statens Serum Institut, Copenhagen, Denmark.
- Antimicrobial Resistance and Infectious Diseases Laboratory, Harry Butler Institute, Murdoch University, Perth, Australia.
ORCID-Profile: Bo Söderquist
Zitieren
APA
Hugg, R., Stegger, M., & Söderquist, B. (2026). Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag218
Vancouver
Hugg R, Stegger M, Söderquist B. Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag218
BibTeX
@article{Hugg2026,
author = {Hugg, Ronja and Stegger, Marc and Söderquist, Bo},
title = {Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag218}
}
EUVIMED